Coherus: Branded Biosimilar Strategy, Cash Reserve, Revenue Stream [Seeking Alpha]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: Seeking Alpha
SummaryCoherus has a strong revenue generating pipeline and 4 upcoming product candidates.It has good cash reserve and just recently did a secondary.It seems like a good stock to buy in a staggered manner.Coherus Biosciences (CHRScaptureRecall that a biosimilar, or biosim, is a generic for biologics. Biologics are drugs genetically derived from living matter, and since they do not have composition of matter patents, are more easily replicated and marketed than small molecule drugs. However, that is only in theory. In many ways, a biologic is more difficult to manufacture than other drugs, so a company like Coherus is relatively well-positioned against other companies in terms of competitive hurdle. That is why Coherus not only develops and commercializes its own biosims, but it also offers these services to others seeking to access the vast US market.Pipeline and trialsCoherus is advancing late-stage clinical products CHS-1420, a Humira® (adalimumab) biosimilar, Bioeq’s Lucentis® (ran
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic AntibodyGlobeNewswire
- Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs OfficerGlobeNewswire
- Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewswire
- Coherus Oncology to Participate in Upcoming Investor ConferencesGlobeNewswire
CHRS
Earnings
- 11/6/25 - Beat
CHRS
Sec Filings
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- 11/4/25 - Form SCHEDULE
- CHRS's page on the SEC website